Core Viewpoint - The stock of Yiming Anke-B (01541) has surged over 10%, currently up 13.82% at HKD 14, with a trading volume of HKD 82.2247 million, following the release of its interim results for the six months ending June 30, 2025, which showed significant revenue growth and promising clinical trial developments [1] Financial Performance - The company reported a revenue of RMB 38.027 million for the interim period, representing a year-on-year increase of 49,285.71% [1] - Research and development expenses amounted to RMB 168 million, reflecting a year-on-year increase of 41.05% [1] Strategic Developments - The revenue increase is primarily attributed to recent payments received from a licensing and collaboration agreement with Axion Bio, Inc. [1] - Pacific Securities has published a report indicating that the company has achieved preliminary safety and efficacy data from its Phase II clinical trial of IMM2510 in combination with chemotherapy for NSCLC patients [1] - The company is planning to initiate a Phase III clinical trial and a Phase I clinical trial for IMM2510 as a monotherapy for recurrent/refractory solid tumors in the United States, expected to start in the second half of 2025 [1] Future Projections - Revenue forecasts for the company are projected to be RMB 151 million, RMB 139 million, and RMB 675 million for the years 2025, 2026, and 2027, respectively [1] - The valuation of the core pipeline is expected to further increase, with a maintained "buy" rating from analysts [1]
宜明昂科-B涨超10% 临床试验取得积极进展 机构维持“买入”评级